Tagged with Clinical

R&D Pfizer Turkey has taken a strong supporting role in Turkey’s current strategic development plan by localizing the production of their Prix Galien winning Prevnar vaccine. Country Manager Elif Aral discusses this facility’s role as a role model in the industry, and how the country can improve investment incentives to better…

AstraZeneca Rodrigo Fernandez became country president of AstraZeneca Central America, Caribbean, and Middle Andean Countries (CAMCARMAC) in July 2013. He discusses the challenges across the region for regulation and distribution channels, with an emphasis on the complexities of the Peruvian market. What were your initial priorities when you became head of…

Celgene Celgene is committed to improving the lives of patients through innovation. The country manager of the recently opened Mexico affiliate explains the importance of having a direct presence in the market, how pro-patients and pro-innovation policies need to be supported, how innovative ways need to be found to ensure patient…

clinical trials The president of the association representing clinical research organisations speaks out about Romania’s attractiveness as a destination country in an era of clinical research globalisation. He further sheds ideas on fostering greater in-country R&D activity and outlines his personal vision for developing the association. How did the association come into…

Ipsen Mexico is a key market for Ipsen to consolidate its footprint in the Americas. The recently appointed general manager and the medical director of the Mexican affiliate discuss how penetrating the market is a hard, yet not impossible mission, how Mexican patients are increasingly involved in Ipsen’s global clinical trials…

Novartis Novartis strives for “creating solutions for patients that go beyond the pill”. The country head and next president of CANIFARMA discusses how the company is using new programs and technology to get innovation to patients, how the recent work of COFEPRIS is helping get drugs to patients faster and why…

CRO Albert Liou discusses the success of the government’s investment in clinical trial infrastructure, which has triggered the rapid growth and advancement of the Korean clinical trial market and spurred innovation in the local life science industry.   What have been some of the main changes for PAREXEL in Korea since…

CRO A senior director for Icon plc discusses Argentina’s strengths and weaknesses as a venue for clinical trials, the role the market plays in a global clinical trial strategy, and Icon’s ambitions for growth in the region.   What are Argentina’s strategic advantages in terms of clinical trial strategy? Argentina in…

clinical trials Dr. Wanda Dobrzanski discusses Argentina’s potential and attractiveness as a clinical research environment and the biggest challenges facing local and global CROs in Argentina.   How has political and popular opposition to clinical trials in Argentina changed over the last five years? Five years ago, the perception of clinical trials…

CRO The opening of the Mexican Social Security Institute (IMSS) to clinical research is a unique opportunity for Mexico to step up on the international scenario for clinical trials. The CEO of Innovare explains how the company is betting on Mexico to conduct clinical R&D and help companies bring innovative drugs to…

stem cell The founder of MEDIPOST, the producer of the only approved allogenic stem cell product in the world, disucsses their development goals for the coming years and the potential for regenerative medicine to revolutionize a variety of healthcare practices. Dr. Yang, to begin, could you please introduce yourself and MEDIPOST to…

clinical research The head of Management Center for the North West Africa of a large multinational speaks out about the defining characteristics of the Algerian pharmaceutical market and discusses the importance of training local medical practitioners in clinical research techniques and methodologies. Now, you are the Head of the Management Center for…